Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TTR | P02766 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | EYA3 | Q99504 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18629882 | 0.91 | CA5A (0.48) | CA5ALMNATTRESR1MEN1 | |
| SCHEMBL6944075 | 0.85 | LMNA (0.78) | CA5ALMNAMEN1KMT2AHTT | |
| SCHEMBL14264012 | 0.84 | TPMT (0.61) | CA5ALMNAESR1KMT2ATPMT | |
| SCHEMBL2122707 | 0.84 | SMN1; SMN2 (0.46) | CA5ALMNAMEN1KMT2AHTT | |
| SCHEMBL14277282 | 0.82 | CA5A (0.48) | CA5ALMNAESR1KMT2ATPMT | |
| SCHEMBL5303103 | 0.81 | TTR (0.52) | LMNATTRESR1MEN1KMT2A | |
| SCHEMBL6721288 | 0.81 | TTR (0.52) | LMNATTRESR1MEN1KMT2A | |
| SCHEMBL22982377 | 0.80 | CA5A (0.46) | CA5ALMNATPMTHPGD | |
| SCHEMBL1613916 | 0.79 | TPMT (0.68) | CA5ALMNATTRESR1MEN1 | |
| SCHEMBL2163724 | 0.79 | TTR (0.50) | LMNATTRESR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136704-A | Compound, polymer, composition for film formation, pattern formation method, method for forming insulating film, and method for producing compound | 三菱瓦斯化学株式会社 | 2025-06-13 | — | — | CN | disclosed |
| CN-120136703-A | Compound, polymer, composition for film formation, pattern formation method, method for forming insulating film, and method for producing compound | 三菱瓦斯化学株式会社 | 2025-06-13 | — | — | CN | disclosed |
| US-11592746-B2 | Radiation-sensitive resin composition, resist pattern-forming method, compound and method of generating acid | JSR CORPORATION (JP) | 2023-02-28 | — | — | US | disclosed |
| WO-2021029395-A1 | COMPOUND, POLYMER, COMPOSITION, COMPOSITION FOR FILM FORMATION, PATTERN FORMING METHOD, METHOD FOR FORMING INSULATING FILM, METHOD FOR PRODUCING COMPOUND, IODINE-CONTAINING VINYL POLYMER AND METHOD FOR PRODUCING ACETYLATED DERIVATIVE OF SAME | 三菱瓦斯化学株式会社 | 2021-02-18 | — | — | WO | disclosed |
| US-20200341376-A1 | RADIATION-SENSITIVE RESIN COMPOSITION, RESIST PATTERN-FORMING METHOD, COMPOUND AND METHOD OF GENERATING ACID | JSR CORPORATION (JP) | 2020-10-29 | — | — | US | disclosed |
| US-20200341376-A1 | RADIATION-SENSITIVE RESIN COMPOSITION, RESIST PATTERN-FORMING METHOD, COMPOUND AND METHOD OF GENERATING ACID | JSR CORPORATION (JP) | 2020-10-29 | — | — | US | disclosed |
| US-20090291924-A1 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291924-A1 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7538252-B2 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538252-B2 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080076737-A1 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076737-A1 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| WO-2008030892-A2 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291924-A1 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | TUBB, TUBA1C, TUBB1 | CA5A 1444/4885LMNA 1792/4885TTR 379/4885 |
| US-20080076737-A1 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | TUBB, TUBA1C, TUBB1 | CA5A 1444/4885LMNA 1792/4885TTR 379/4885 |
| US-20200341376-A1 | RADIATION-SENSITIVE RESIN COMPOSITION, RESIST PATTERN-FORMING METHOD, COMPOUND AND METHOD OF GENERATING ACID | RER1, TAS1R1, RAD51 | CA5A 2014/4885LMNA 3976/4885TTR 4534/4885 |
| US-11592746-B2 | Radiation-sensitive resin composition, resist pattern-forming method, compound and method of generating acid | RER1, TAS1R1, RAD51 | CA5A 2014/4885LMNA 3976/4885TTR 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.